Journal: Biomaterials Research

Article Title: Rescue Radiosensitization of Pancreatic Cancer via PD-L1/TGF-β1 Dual-Blockade Nanotherapy as Evaluated in 3-Dimensional Microtumors

doi: 10.34133/bmr.0335

Figure Lengend Snippet: The biological multifunctional therapeutic effect of PFD@NGHP was assessed through a comprehensive evaluation. (A) Establishment schematic of Transwell assay system to evaluate the proliferation inhibition of PFD@NGHP. (B) Cell viability of PSCs determined by Transwell assay system. PFD@NGHP exhibited the most potent inhibitory profile. (C) Cell viability of different cell lines (PANC-1 cells, hPSCs, PANC02 cells, and mPSCs) was assessed via CCK-8 kit after different treatments including combination therapy or monotherapy. (D) Expression levels of collagen I, TGF-β1, α-SMA and α-tubulin in hPSC and mPSC lines treated under different conditions for 48 h, as determined by Western blotting. Con, control. (E) TGF-β1 secretion of hPSC and human cell coculture system (H-Co) under different conditions was evaluated by ELISA. Irradiated (RT+) cells and unirradiated (RT−) cells were both analyzed. (F) TGF-β1 secretion of mPSC and mouse cell coculture system (M-Co) under different conditions was evaluated by ELISA. Irradiated cells and unirradiated cells were both analyzed. (G) FCM analysis of PD-L1-targeting by NGHP in PANC-1 and PAN02 cells. NC, negative control. (H) ADCC assay was used to assess the functional status of αPD-L1 in NGHP. ADCC in PANC-1 and IR-PANC-1 (irradiated PANC-1) cells, mediated by different samples (“mNG” was mPEGS-nanogel), was induced using PBMC. All data are exhibited as the means ± SD ( n = 3), and the inserted asterisks indicate statistically significant differences based on * P < 0.05, ** P < 0.01, and *** P < 0.001.

Article Snippet: The human peripheral blood mononuclear cells (PBMCs) were purchased from iXCells Biotechnologies (CA, USA).

Techniques: Transwell Assay, Inhibition, CCK-8 Assay, Expressing, Western Blot, Control, Enzyme-linked Immunosorbent Assay, Irradiation, Negative Control, ADCC Assay, Functional Assay

Journal: medRxiv

Article Title: Circulating Cell Type Senescence Signatures Reveal High-Resolution Health Status and Trajectories in Human Longitudinal Studies

doi: 10.64898/2026.02.06.26345739

Figure Lengend Snippet: A) Among all SAPs identified in at least two induction methods for each cell type in the SenCat, elastic net modeling revealed senescence signatures associated with mortality. Linear modeling revealed each signature association with age using the formula age ∼ protein + sex + race, and their average log2 fold-change (LFC Sen/Pro) in each cell type across two induction methods is shown. B) Tracking longitudinal health trajectories reveals higher mortality among those in the highest quartile mean composite senescence score of these SAPs compared to those in the lowest quartile. C) Up to 25 elastic net selected SAPs were selected from cell type senescence signatures as implicated in a diabetes onset, which were each compiled into a mean composite score to represent cell type senescence burden. The association between the cell type senescence burden and diabetes onset via cox proportional hazards modeling in the BLSA using the formula: event/age or last age ∼ composite score + sex + race. D) Tracking longitudinal health trajectories reveals higher diabetes probabilities among those in the highest quartile composite score of PBMC SAPs compared to those in the lowest quartile. *For Sen/Pro LFC, only proteins significantly elevated in each cell type using two induction methods are depicted by their average LFC across both induction methods.

Article Snippet: All cell types from the SenCat are of human origin, and include WI-38 lung fibroblasts (obtained from the NIGMS Human Genetic Cell Repository, Coriell Institute for Medical Research; repository ID AG06814-N), BJ skin fibroblasts (ATCC, CRL-2522), HSAEC lung epithelial cells (ATCC, PCS-301-010, HEKn epidermal skin keratinocytes (ATCC, PCS-200-010), HCAEC coronary artery endothelial cells (LifeLine Cell Technology, FC-0032), HUVEC umbilical vein endothelial cells (ATCC, PCS-100-010), HVSMC coronary artery smooth muscle cells (LifeLine Cell Technology, FC-0031), HSKM skeletal myoblasts (Gibco, A12555), PBMC peripheral blood mononuclear cells (ATCC, PCS-800-011), PreAdipo subcutaneous preadipocytes (ATCC, PCS-210-010), NHO osteoblasts (Lonza, CC-2538), NHA astrocytes (Lonza, CC-2565), HEMn melanocytes (ATCC, PCS-200-012), and HREC renal epithelial cells.

Techniques: